Cyclin D1 Expression, Clinicopathological Characteristics, and 2-Year Survival Rate of Gastric Cancer in Cipto Mangunkusumo General Hospital

• Published in: Nigerian journal of clinical practice Vol. 26; no. 8; pp. 1057 - 1062
• Main Authors: Cahyanur, R, Utari, AP, Rahadiani, N
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer - Medknow 01.08.2023; Medknow Publications and Media Pvt. Ltd
• Edition: 2
• Subjects: Cancer; Chemotherapy; Cyclin D proteins; Development and progression; Health aspects; Metastasis; Oncology, Experimental; Original Article; Patient outcomes; Physiological aspects; Prognosis; Stomach cancer; Indonesia
• ISSN: 1119-3077; 2229-7731
• DOI: 10.4103/njcp.njcp_222_22

ABSTRACT Background: Cyclin D1 is a protein that can increase the proliferation of cancer cells. Its expression has been found in various malignancies, including gastric cancer. Cyclin D1 examinations have not been routinely performed for gastric cancer cases in Indonesia. A recent study of cyclin D1 in gastric cancer was associated with lymph node involvement, metastasis, poor prognosis, and a lack of response to platinum chemotherapy. Aim: This study aimed to determine the relationships among cyclin D1 expression, clinicopathological features, and 2-year survival rates in gastric cancer. Materials and Methods: This retrospective cohort study used medical records and paraffin blocks of patients suffering from gastric cancer at Cipto Mangunkusumo General Hospital, Jakarta, between 2015 and 2020. Data analysis was performed using Statistical Package for the Social Sciences (SPSS) version 20. The data were collected from 39 subjects, most of whom experienced eating disorder (69.23%), weight loss (76.92%), melena (53.85%), and anemia (51.28%). Tumor location was mostly found in the cardia and corpus of the gaster. Results: This study found that the proportion of overexpression of cyclin D1 was 30.77%. Cyclin D1 expression was greater in subjects with liver metastases (50% vs. 14.8%, P = 0.04). Cyclin D1 expression was not associated with tumor location, tumor, node, and metastasis (TNM) stage, or histopathological findings. Analysis of the 2-year survival rate did not find any differences between patients with cyclin D1 overexpression and those with cyclin D1 negative. Conclusions: Cyclin D1 expression was associated with liver metastases in patients with gastric cancer.